- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04029571
Effect and Safety of TCM-FMD in Phlegm-Dampness Type Overweight/Obesity Patients(EASTAR)
Effect and Safety of Fasting-Mimicking Diet Combined With a "Dispelling Dampness" Meal Replacement in Phlegm-Dampness Type Overweight/Obesity Patients: A Randomized Controlled Study(EASTAR)
Study Overview
Detailed Description
Background:Fasting-mimiking Diet (FMD) is a plant-based diet designed to attain fasting-like effect, firstly proposed on 2015[1]. It requires people to limit calorie intake for 5 continuous days, and then return to their normal diet after completion about 25 days until the next cycle. In a clinical trial[2], three FMD cycles reduced body weight, trunk and body fat, and reduced blood pressure, fasting blood glucose, triglycerides and total cholesterol. On the other hand, in the theory of physique of TCM theory, overweight/obesity is usually considered to be phlegm-dampness type.
Objective: We assume that using medicinal-edible plants which was considered to dispel dampness(such as fuling, shanyao, etc.) as FMD's proprietary formulations can enhance the effect of FMD on improve people's characteristic features of metabolic syndrome.
Methods: A 12-week, single-center, pilot study will be conducted to test the study objectives.A new diet is carried. It is a fasting-mimicking diet combined with a "dispelling dampness" meal replacement. Because the theory of applying traditional Chinese medicine combined with FMD, we call it TCM-FMD, the main ingredient of the "wet diet" meal package is millet. Brown rice, oats, purple sweet potato, alfalfa, yam, hazelnut, etc. For comparison, we also designed FMD to make some cereals (including millet, purple potato, oatmeal, walnut, etc.) without a moisturizing effect into a "grain package" as a control group. Both groups were administered using the FMD diet model. At the same time, a group of normal diets was also designed as a blank control group. The primary outcome measure for the study was weight; secondary outcome measures included: waist circumference, blood pressure, triglycerides, total cholesterol and fasting blood glucose, quality of life (evaluated by physical fitness scale and SF-36); safety indicators included: liver and kidney Features, etc. Both groups were subjected to caloric restriction (5 days, daily calorie about 800kcal) and normal diet (dietitian for healthy diet guidance), and the blank control group was given a normal diet.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510000
- Guangdong Provincial Hospital of Chinese Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosed as overweight / obesity according to the "China Adult Obesity Prevention and Treatment Expert Consensus"
- Diagnosis as phlegm-dampness type according to the "Traditional Chinese Medicine Classification and Judgment" scale published by the Chinese Medicine Association
- 18 years old ≤ age ≤ 65 years old
- Signed the informed consent
Exclusion Criteria:
- Those who have special food requirements or having a history of food allergies
- Those who have history of previous diabetes, or body weight loss, BMI ≤ 18
- Those who have had cardiovascular and cerebrovascular events within half a year, or who have a major history of surgery
- Pregnant or lactating woman
- Those who have severe primary diseases such as liver or kidney diseases, as well as abnormalities in the hematopoietic system and mental disorders
- Those who need to take special drugs (such as hormones)
- Those who refuse to provide information required for research (such as personal information, blood samples, etc.)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: TCM-FMD
Apply fastening-mimicking diet combined with a "dispelling dampness" meal replacement.
For the convenience of implementation, a cycle of 4 weeks.
The first 5 days of each cycle is the calorie restriction stage (daily calorie about 800kcal).
The traditional Chinese medicine with dampness effect is used as the main source of calories in this stage.
The normal diet is carried out under the guidance of a professional dietitian for the next 23 days.
Study for 12 weeks.
|
Apply fastening-mimicking diet combined with a "dispelling dampness" meal replacement.
For the convenience of implementation, a cycle of 4 weeks.
The first 5 days of each cycle is the calorie restriction stage (daily calorie about 800kcal).
The traditional Chinese medicine with dampness effect is used as the main source of calories in this stage.
The normal diet is carried out under the guidance of a professional dietitian for the next 23 days.
Study for 12 weeks.
|
|
Active Comparator: FMD
A "grain package" is used to replace the "dispelling dampness" meal replacement, and the other thing is the same as the proposal in TCM-FMD.
|
A "grain package" is used to replace the "dispelling dampness" meal replacement, and the other thing is the same as the proposal in TCM-FMD.
|
|
No Intervention: Normal diet
Carrying out normal diet under the guidance of a dietitian, for 12 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Body weight
Time Frame: Change from baseline to day 6/week 4/week 12
|
Measuring the fasting weight of the day at the required time point and measured by the same instrument
|
Change from baseline to day 6/week 4/week 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Triglycerides
Time Frame: Change from baseline to week 4/week 12
|
Measured by GPO-PAP enzymatic method
|
Change from baseline to week 4/week 12
|
|
Fasting glucose
Time Frame: Change from baseline to week 4/week 12
|
Measured by Hexokinase
|
Change from baseline to week 4/week 12
|
|
Blood pressure
Time Frame: Change from baseline to week 4/week 12
|
Measure by the same sphygmomanometer
|
Change from baseline to week 4/week 12
|
Collaborators and Investigators
Investigators
- Study Director: Yuanqi Zhao, MD, Guangdong Provincial Hospital of Traditional Chinese Medicine
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- tcmfmd
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Dr. Christopher McGowanRecruitingObesity Prevention | Obesity Recidivism | Obesity and Overweight | Obesity and Obesity-related Medical ConditionsUnited States
-
Central Hospital, Nancy, FranceNot yet recruiting
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsCompletedOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
The Hospital for Sick ChildrenCompleted
-
Ihuoma EneliCompletedObesity, ChildhoodUnited States
-
Dr. Christopher McGowanRecruitingObesity Prevention | Obesity Recidivism | Obesity and Overweight | GLP-1 | Obesity and Obesity-related Medical Conditions | Ablation TechniquesUnited States
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
Clinical Trials on TCM-FMD
-
University Hospital, MontpellierUniversity Hospital, ParisTerminatedHealthy | COPD PatientsFrance
-
Fondazione IRCCS Istituto Nazionale dei Tumori,...Institut National de la Santé Et de la Recherche Médicale, France; Martin-Luther-Universität... and other collaboratorsUnknownBreast Cancer | Melanoma, MalignantItaly
-
Postgraduate Institute of Dental Sciences RohtakUnknown
-
AcusMu Medtech Co., Ltd.Taipei Medical University HospitalCompleted
-
University of ChileAgencia Nacional de Investigación y DesarrolloRecruitingStroke | Myocardial Injury | Surgery | Cardiac DeathChile
-
Henan University of Traditional Chinese MedicineCompleted
-
Henan University of Traditional Chinese MedicineShanghai University of Traditional Chinese Medicine; Shaanxi Hospital of Traditional... and other collaboratorsNot yet recruiting
-
Uniter OnlusUniversity of Rome Tor VergataCompletedObesity | Diet, Healthy | Olfaction DisordersItaly
-
Henan University of Traditional Chinese MedicineUnknownPulmonary Disease, Chronic Obstructive | Medicine, Chinese Traditional | Acute Exacerbation
-
NHS Greater Glasgow and ClydeUniversity of GlasgowCompletedHypertension | COVIDUnited Kingdom